UK Mounjaro warning issued ahead of heatwave temperatures
It's estimated that around 1.5 million Brits are now taking weight-loss drugs, with numbers increasing each week.
The last year has seen a huge increase in the number of people taking GLP-1 receptor agonists, some prescribed by the NHS and others by private doctors, with common injectibles including semaglutide (Wegovy and Ozempic), tirzepatide (Mounjaro) and liraglutide (Saxenda).
As the temperatures rise, experts are stressing that users must store weight loss injections in a refrigerator (2-8°C or 36-46°F), especially after starting the course.
Review your ICB's local policy about treating patients with tirzepatide (Mounjaro) for weight management in a primary care setting and visit: https://t.co/03msJjjTU9 pic.twitter.com/tHs6lyJHc4 — We are Primary Care (@PrimaryCareNHS) June 12, 2025
'Weight loss injections can be adversely affected by hot weather, particularly regarding storage and stability," says James O'Loan, obesity specialist and weight loss injection expert at pharmacists Chemist4U.
"Understanding the storage instructions when using any prescribed medication is vital to keep it in optimal condition.
"Although weight loss injections can be stored at room temperature for up to 30 days (some injections are 42 days, so always check with your prescriber or refer to the patient information leaflet), this is only provided the temperature does not exceed 30°C. During hot weather, and to be on the safe side, it is always best to keep your weight loss injections refrigerated if you're able."
Can I take my Mounjaro pen on holiday?
The advice for the UK heatwave is also also worth noting for those heading on holiday or travelling during the warmer weather.
However, if you're flying, remember to pack your injections in your carry-on since the baggage hold on a plane can plummet to below-freezing temperatures.
Finding the right temperature for your pen is important: not too hot or too cold. If you inject after incorrectly storing your pen, it might not be safe for use.
How do I know if my Mounjaro pen is safe to use?
"There are a few important things to consider when checking if your weight loss pen is safe to use," says James.
"Inspect the pen to ensure it is not damaged and the medicine inside is clear, with no particles or cloudiness. The liquid should be colourless or slightly yellow. If you have left your pen unrefrigerated during hot weather and are unsure whether it is still safe to use, always consult your prescriber before injecting.
"Staying hydrated whilst taking weight loss injections is key. Weight loss injections can cause side effects such as nausea, constipation, diarrhoea and dizziness, which, without sufficient fluids, can lead to dehydration.
"We recommend drinking plenty of water throughout the day, even when you're not thirsty. If experiencing diarrhoea or vomiting, try using electrolyte drinks, rehydrate quickly and apply sunscreen whenever you are outdoors. This will help those who suffer from heightened sensitivity to UV rays.'
Do you need to tell your travel insurance you are taking Mounjaro?
Yes. Travel insurance providers are warning that the growing number of Brits turning to these breakthrough drugs for weight management could lose their cover and face huge medical bills abroad if they don't declare their usage when arranging travel insurance.
Many don't want to admit they are taking the weight-loss drugs, or think that if they buy it privately, it doesn't need to be declared.
Niraj Mamtora, director at Forum Insurance, says: 'Weight-loss medications like Ozempic are transforming lives across the UK, but too many travellers don't realise the insurance implications. If you're using these drugs, you must declare both the medication and the condition it's prescribed for.
'Failure to do so is not a minor oversight - it's a serious breach of your travel insurance contract. If you need medical help overseas and haven't declared your medication, your claim can be refused and your policy cancelled. The financial consequences can be severe.'
Recommended reading:
What happens if you don't disclose weight-loss jabs on your travel insurance?
'Non-disclosure is a gamble that's simply not worth taking," says Niraj.
"If you don't declare your medication or the underlying condition, your insurer is within their rights to refuse any claim, even if it seems unrelated.
'Many travellers only discover too late that their travel insurance claims are rejected, leaving them without support and facing potentially huge bills.
"With the average medical claim abroad now exceeding £1,700, and costs rising significantly with age, being properly covered is more important than ever.'
Insurance claims related to undeclared conditions or medications can be refused, even if the issue seems unrelated.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
an hour ago
- The Guardian
Two Leeds hospitals' maternity services rated inadequate over safety risks
The care of women and babies at two Leeds hospitals presents a significant risk to their safety, the NHS regulator has said, after the preventable deaths of dozens of newborns. The Care Quality Commission (CQC) demanded urgent improvements to maternity services at Leeds general infirmary and St James's hospital as it downgraded them to 'inadequate'. A BBC investigation this year found that the deaths of at least 56 babies and two mothers may have been preventable at the two hospitals between January 2019 and July 2024. The hospitals, run by Leeds teaching hospitals NHS trust, are the latest to be engulfed by a maternity scandal that has revealed catastrophic failings in Nottingham, Shrewsbury and Telford, Morecambe Bay, east Kent and others. The downgrading of maternity and neonatal services in Leeds follows unannounced inspections by the CQC in December and January. Ann Ford, a director of operations at the CQC, said it had received concerns from staff, patients and families about safety and staffing levels at the two hospitals. She said: 'During the inspection the concerns were substantiated, and this posed a significant risk to the safety of women, people using these services, and their babies as the staff shortages impacted on the timeliness of the care and support they received.' Inspectors found dirty areas on the maternity wards of both hospitals, unsafe storage of medicines, a 'blame culture' that left staff unwilling to raise concerns, and short-staffed units. On the neonatal wards, which care for the most vulnerable newborns, the CQC found they were understaffed and infants needing special care were being transported unsafely from one hospital to another. A freedom of information request by the BBC revealed in January that the NHS trust had identified at least 56 baby deaths that may have been preventable from January 2019 to July 2024, made up of 27 stillbirths and 29 neonatal deaths, which are deaths within 28 days after birth. In each case, a trust review group had identified care issues it considered may have made a difference to the outcome for babies. Sir Julian Hartley, the head of the CQC, was the chief executive of Leeds teaching hospitals NHS trust for 10 years until January 2023, meaning he was in charge when many of the preventable deaths took place. The parents of a newborn girl who died after multiple failings at Leeds general infirmary in January 2020 questioned the CQC's ability to carry out an independent inspection, given Hartley's previous role. The regulator said it has 'robust policies in place to manage any conflict of interest'. Prof Phil Wood, the chief executive of Leeds teaching hospitals NHS trust, said: 'These reports have highlighted significant areas where we need to improve our maternity and neonatal services, and my priority is to make sure we urgently take action to deliver these improvements.' He said the trust was improving whistleblowing procedures for staff and had recruited 55 midwives, leaving it 11 short of the national target. Wood added: 'I want to reassure every family due to have their baby with us in Leeds and any new parents that we are absolutely committed to providing safe, compassionate care.'
Daily Mirror
3 hours ago
- Daily Mirror
Symptom that hits '3 times in 24 hours' could signal Covid
The latest figures also highlighted two of the most dominant Covid variants at the moment People should stay vigilant for signs of COVID-19 as there's been a marginal uptick in cases across the UK. Government data reveals that in the week up to June 15, there has been an increase in the number of confirmed Covid infections in England. This included people in hospital who were given PCR tests. Hospital admissions due to coronavirus also increased slightly compared to the previous week. The predominant strains circulating during that time were identified as LP. 8.1.1 and XFG, each contributing to 19.87 per cent of the reported cases. Also present was the "Nimbus" strain or NB.1.8.1, representing 3.97 per cent of infections. LP. 8.1.1 evolved from LP. 8.1 which itself is a descendant of Omicron, with the original LP.8.1 having surfaced in July 2024 and later categorised as a "variant under monitoring" by WHO in January. Symptoms Currently, it remains uncertain whether LP. 8.1.1 triggers specific symptoms distinctive from other strains. Thomas Jeffries, a senior microbiology lecturer at Western Sydney University, observed that LP.8.1 does not seem to be responsible for exceptionally severe symptoms. Writing for The Conversation, he said: "Notably, the symptoms of LP.8.1 don't appear to be any more severe than other circulating strains. And the WHO has evaluated the additional public health risk LP.8.1 poses at a global level to be low. "What's more, LP.8.1 remains a variant under monitoring, rather than a variant of interest or a variant of concern. In other words, these changes to the virus with LP.8.1 are small, and not likely to make a big difference to the trajectory of the pandemic." However, according to the NHS, one definitive symptom of Covid is a new or persistent cough, which may involve three or more "coughing episodes" in 24 hours. Other indicators on the list are: A high temperature or shivering (chills) – a high temperature means you feel hot to touch on your chest or back (you do not need to measure your temperature) A loss or change to your sense of smell or taste Shortness of breath Feeling tired or exhausted An aching body A headache A sore throat A blocked or runny nose Loss of appetite Diarrhoea Feeling sick or being sick. The NHS guidance for those with symptoms of Covid suggests self-isolation until recovery. For those who receive a positive Covid test result, the NHS advocates staying home and away from others for five days, although it's not legally required. Further analysis of recent Covid statistics reveals that the weekly mean positivity rate for PCR tests in English hospitals was up slightly at 6.6 per cent for the week leading up to June 15, compared to 6.2 per cent in the prior week. The total weekly hospital admission rate for COVID-19 saw a slight rise to 1.53 per 100,000 from the previous week's 1.44 per 100,000. However, the overall rate of COVID-19 patients in ICU or HDU remained steady at 0.04 per 100,000, mirroring the previous week's figure.
South Wales Guardian
3 hours ago
- South Wales Guardian
Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases. This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added. It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service. The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost. Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases. After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials. Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses. Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's. Trial results for the Alzheimer's trial are expected to be published later this year. Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process. 'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.' Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs. 'Getting multiple drugs that are targeting the disease is really important to us,' she said. 'Testing different types of drugs and getting as many shots on target is important.' She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process. 'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.' Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'. She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas. 'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies. 'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.' She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS. And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment. 'They showed for the very first time that we were able to alter the course of the disease. 'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.' Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker. 'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
